XenoFarma, in collaboration with Erbozeta – Energia Verde (Italy), successfully organized a Round Table Discussion (RTD) with a group of leading urologists in Baghdad on Thursday, December 5, 2025.
The scientific session focused on “Erbozeta’s Approach in the Management of Nephrolithiasis”, with special emphasis on URO3 Plus as a supportive option in the prevention and management of urinary stone disease. During the presentation, current clinical challenges in nephrolithiasis were discussed, including recurrence prevention, patient compliance, and long-term metabolic management.
The discussion highlighted the mechanism of action, clinical benefits, and real-world use of URO3 Plus, supported by scientific evidence and practical experience from daily urology practice. Participating physicians actively exchanged insights on patient selection, adjunctive therapy, and integration of nutraceuticals into standard urological care.
The RTD provided an interactive platform for open dialogue, allowing urologists to share case-based experiences and discuss modern strategies aimed at improving patient outcomes while reducing stone recurrence.
XenoFarma remains committed to supporting continuous medical education and fostering scientific exchange through focused, high-quality meetings with healthcare professionals across Iraq.
Event Details
- Event Type: Round Table Discussion (RTD)
- Specialty: Urology
- Topic: Management of Nephrolithiasis – Erbozeta Touch
- Product Highlight: URO3 Plus
- Date: December 5, 2025
- Location: Baghdad, Iraq
